Compare ServiceNow Inc (NOW) vs Summit Therapeutics Inc (SMMT) Price & Performance

ServiceNow (NOW) trades at $131.11, down 7.19% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew from $7.2B in 2022 to $13.28B in 2025, though net income margin has fluctuated. Positive sentiment is driven by AI integration and conference presentations, while high valuation ratios like a P/E of 83.88 present risks.

The outlook remains positive due to robust revenue growth and AI-driven business expansion, but elevated valuations and competitive pressures warrant caution. Analyst consensus is strongly bullish with a $141.46 price target, though investors should monitor execution risks and macroeconomic headwinds that could impact future performance.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.